MOLECULIN BIOTECH INC
MBRXNASDAQTrading Snapshot
- Day Range
- $6.86 β $8.03
- 52-Week Range
- $3.22 β $222.80
- Volume (shares)
- 1,695
- Avg Volume (shares)
- β
- Shares Outstanding
- 1.0M
- Next Earnings
- 2027-03-16
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -0.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-15.07
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2267.0%
MOLECULIN BIOTECH INC
MBRXAbout MOLECULIN BIOTECH INC
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance
Patent protection spans North America, Europe & Asia-Pacific Rim Korean decision to grant extends reconstitution protection into another key Asia-Pacific market, reinforcing a multi-layered portfolio spanning more than 2

Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
- Completed treatment of all 90 patients in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML)

Moleculin Secures Australian Patent for Annamycin Formulation Technology
Patent strengthens intellectual property protection for preparation of preliposomal Annamycin lyophilizate

Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin's antitumor activity, not a bystander

Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML

Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML)